Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis Abstract #144

Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Aim(s): To evaluate the activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NECs.
Materials and methods: We reviewed the clinical records of patients with a histological diagnosis of NECs, progressive advanced unresectable disease, treated with an oxaliplatin-based regimen. The tumors were defined according to WHO 2000 and TNM 2006 classifications. Response rate (RR), time to progression (TTP), toxicity, and survival were calculated. The tissue tumor samples were centrally (IEO) analysed to detect Ki-67, and excision repair cross-complementing group-1 (ERCC-1).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Francesca Spada

To read results and conclusion, please login ...

Further abstracts you may be interested in

#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Conference:
Category: Basic
Presenting Author: MD FRANCESCA SPADA
#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study
Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Haamid Jan
Authors: Jan H, Wyld D, Burge M, ...
#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: Oxaliplatin, NETs
#1774 Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs
Introduction: In Romania, treatment with somatostatin analogs (SSA) for neuroendocrine tumors (NETs) is based on the National Clinical Practice Guideline for the Diagnostic and Treatment of NETs and is reimbursed by the National Health Insurance Company since 2008.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD, Prof. Fica Simona
#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference: 17th Annual ENETS Conference (2020)
Category: Case reports
Presenting Author: MD, PhD, Lecture Carmen Sorina Martin
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team